Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine in Recurrent IDH1/2 Mutated Gliomas
NCT03666559Phase 2Active, not recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2020
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in glioma, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Progression-Free Survival at 6 months. Started Sep 2020; status: active, not recruiting.
02
Drugs
azacitidine
03
Conditions
glioma
Beyond the preview
Go deeper on NCT03666559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03666559.